StockData
Tango Therapeutics, Inc. logo

Tango Therapeutics, Inc. (TNGX) stock

TNGXNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 10/30128% above fair value
$22.11−2.06 (-8.52%)

Close on Nov 17, 2026Market cap $3.73BP/E –Yield –

Tango Therapeutics cash

Cash and short-term investments held at the end of each period.

Tango Therapeutics's cash was $1.00B at Jun 30, 2026. For fiscal 2025 it was $343.10M, up 33.0% from the year before. The highest annual figure on record is $485.26M in fiscal 2021.

Annual cash

PeriodPeriod endValueChange
FY2025Dec 31, 2025$343.10M+33.0%
FY2024Dec 31, 2024$257.90M-23.4%
FY2023Dec 31, 2023$336.89M-8.0%
FY2022Dec 31, 2022$366.13M-24.5%
FY2021Dec 31, 2021$485.26M+155.0%
FY2020Dec 31, 2020$190.32M–

Quarterly cash

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$1.00B+453.1%
Q1 FY2026Mar 31, 2026$379.80M+75.3%
Q4 FY2025Dec 31, 2025$343.10M+33.0%
Q3 FY2025Sep 30, 2025$152.80M-47.9%
Q2 FY2025Jun 30, 2025$180.80M-43.9%
Q1 FY2025Mar 31, 2025$216.70M-36.9%
Q4 FY2024Dec 31, 2024$257.90M-23.4%
Q3 FY2024Sep 30, 2024$293.28M-18.5%
Q2 FY2024Jun 30, 2024$322.11M+3.7%
Q1 FY2024Mar 31, 2024$343.60M+3.0%
Q4 FY2023Dec 31, 2023$336.89M-8.0%
Q3 FY2023Sep 30, 2023$359.88M-8.5%
Q2 FY2023Jun 30, 2023$310.65M-25.4%
Q1 FY2023Mar 31, 2023$333.64M-25.8%
Q4 FY2022Dec 31, 2022$366.13M-24.5%
Q3 FY2022Sep 30, 2022$393.29M-21.9%
Q2 FY2022Jun 30, 2022$416.36M+71323.7%
Q1 FY2022Mar 31, 2022$449.89M+35649.0%
Q4 FY2021Dec 31, 2021$485.26M+155.0%
Q3 FY2021Sep 30, 2021$503.81M+32356.9%
Q2 FY2021Jun 30, 2021$582.94K+2232.4%
Q1 FY2021Mar 31, 2021$1.26M–
Q4 FY2020Dec 31, 2020$190.32M–
Q3 FY2020Sep 30, 2020$1.55M–
Q2 FY2020Jun 30, 2020$24.99K–

More Tango Therapeutics figures

See a number that looks wrong?